Wall Street is positive on Recursion Pharmaceuticals Inc (RXRX). On average, analysts give RXRX a Buy rating. The average price target is $13.4, which means analysts expect the stock to increase by 57.28% over the next twelve months. That average ranking earns RXRX an Analyst Rating of 18, which is better than 18% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating RXRX a Buy today. Find out what this means to you and get the rest of the rankings on RXRX!